Thu07182019

Robins Global News & Noticias



  • Gaming Chair Review
    Gaming Chair Review
  • Data Recovery Review
    Data Recovery Review
  • Online Video Editors
    Online Video Editors
  • Download TV Series
    Download TV Series
  • All Elite Wrestling
    All Elite Wrestling
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting


REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 abstracts at the ASCO Annual Meeting detailing new insights into precision oncology generated from its commercially available Guardant360 and GuardantOMNI assays, as well as its research-use-only (RUO) LUNAR liquid biopsy.
For patients with advanced cancer, these include multiple investigations of the GuardantOMNI assay’s ability to identify patients who may benefit from treatment with immunotherapy. Additionally, researchers will present Guardant360 data to demonstrate the effectiveness of new targeted drugs, as well as the feasibility of serial ctDNA analysis to rapidly predict treatment response and long-term clinical benefit.For patients with early stage disease, the presentations include an analytical validation of Guardant’s LUNAR assay (Abstract 3057), as well as a pilot study exploring the LUNAR assay’s ability to identify early-stage colorectal cancer patients who may benefit from adjuvant therapy after undergoing an intervention with curative intent (Abstract 3602). This is a particularly challenging clinical setting for the detection of circulating tumor DNA in blood because patients who have undergone curative-intent interventions typically have little-to-no evidence of disease, and very low residual tumor DNA shedding in circulation.“Guardant is committed to expanding the benefits of precision oncology across the continuum of care,” said Guardant Health Chief Medical Officer Dr. Richard Lanman. “The new insights we and our research partners will bring to ASCO this year continue to demonstrate the many advantages of blood-based genomic testing over tissue-based genomic testing in support of a blood-first paradigm in early stage and late stage cancer.”Guardant’s data will be featured in the following presentations at ASCO this year:About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower ...


Posted: 2019-05-16 01:52:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Lifting the Burden: How the Raymond Foundation Helps to Support Caregivers

Wed, 17 Jul 2019 06:08:00 GMT

CURE sat down with Martha Raymond, executive director of GICA and founder of the Raymond Foundation, at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting to ... a road map through ...

Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting

Wed, 15 May 2019 19:10:00 GMT

REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 ...

Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting

Wed, 15 May 2019 19:07:00 GMT

REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 ...

Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting

Wed, 15 May 2019 14:53:00 GMT

REDWOOD CITY, May 15, 2019 (GLOBE NEWSWIRE via COMTEX) -- REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. GH, +0.00% along with researchers from leading academic ...

Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting

Tue, 14 May 2019 17:00:00 GMT

REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 abstracts at ...

Related Twitter Search

  • No items found
  • Related News Story Videos From Youtube

    Dr. Monica Bertagnolli Invites You to the 2019 ASCO Annual Meeting


    Related Videos On: Dr. Monica Bertagnolli Invites You to the 2019 ASCO Annual Meeting


    Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018


    Related Videos On: Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018


    Multidisciplinary Management of Metastatic Colorectal Cancer


    Related Videos On: Multidisciplinary Management of Metastatic Colorectal Cancer


    56th ASH Annual Meeting and Exposition [2014]


    Related Videos On: 56th ASH Annual Meeting and Exposition [2014]


    Fortunato Ciardiello: My Presidency in 4 words


    Related Videos On: Fortunato Ciardiello: My Presidency in 4 words






    Blow Us A Whistle

    Comments (Whistles) Designed By Disqus




    Company Information

    Official Content Providers











    PRIVACY POLICY

    We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
    © 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
    RobinsPost provides links to news sites based on their RSS feeds.
    All trademarks, copyrights, videos, photos and logos are owned by news sources.
    News stories, videos and live streams are from trusted sources:
    Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
    ROBINSPOST Is Proudly Made In America.
    Where Quality, Safety and Service Comes First.